Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
Herbert Smith Freehills Kramer advises global asset manager on sale of C3 and Pedersen businesses to InfraRed Capital Partners
Herbert Smith Freehills Kramer (HSF Kramer) has advised a global asset manager on the Australian aspects of its sale of C3 Limited (C3), a New …
Herbert Smith Freehills Kramer hires a team of legal engineers
Legal engineers will join global law firm from leading AI native firm in the coming weeks
Herbert Smith Freehills Kramer advises Morgan AI on A$3.65 million seed round
HSF Kramer has advised Morgan AI on its A$3.65 million capital raise. The round was led by Blackbird Ventures, with participation from Black Sheep …
Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead